Open Access

Integrating COPD care in Italy

Multidisciplinary Respiratory Medicine20149:26

DOI: 10.1186/2049-6958-9-26

Received: 25 April 2014

Accepted: 25 April 2014

Published: 19 May 2014

Doctors are not short of advice about how to manage their patients. In the case of COPD (Chronic Obstructive Pulmonary Disease) there are a wealth of guidelines, strategies and position papers synthesising an increasing body of data from observational studies and clinical trials into schemes that should help the doctor care for their COPD patients more effectively. In recent years particular attention has been paid to the views of the joint ERS/ATS COPD guidelines [1] and the regularly updated recommendations of the Global initiative for chronic Obstructive Lung Disease (GOLD) [2]. Now a new Italian document has been developed representing the combined efforts of three key Italian respiratory societies AIMAR, AIPO, SIMeR and the society of General Practice, SIMG, whose combined expertise covers almost all those who offer care to the COPD patient. So what does this new guidance tell us and does it add to what we have heard already?

Appropriately this new document takes a very wide view of the problems of COPD. It emphasises the need for early accurate diagnosis supported when needed but supplementary physiological investigations such as the measurement of lung volumes and airway responsiveness. It points out the limitations of relying on a fixed FEV1/FVC ratio of 70% or less to support the diagnosis of COPD and suggest instead that the lower limit of normal (LLN) for this ratio is a more reliable guide. There might have been a little more advice for the busy clinician on the best way of accessing appropriate LLN data and perhaps a little more caution on the usefulness of bronchodilator testing in patient evaluation [3]. However there are some excellent figures to guide diagnosis and management as well as useful tabular summaries of what tests should be undertaken by which clinicians and how to approach smoking cessation.

The authors have avoided some of the controversy and uncertainty surrounding the new GOLD severity assessment scheme [4], instead focussing on patient sub-groups that correspond to those seen in clinical practice and in clinical trials. Their treatment recommendations are not formally evidence based but closely follow those in guidelines where more extensive evidence evaluations have been conducted [5]. The authors offer clear practical guidance with support from selected but relevant literature citations which help the clinician understand why particular treatment choices have been made. There is an appropriate and pragmatic section emphasising the value of pulmonary rehabilitation together with a particularly helpful review of the role of telemedicine in COPD care, a topic scarcely touched on in other guidelines.

This new approach to COPD care is needed in Italy now. As the authors point out, COPD remains a major health problem despite much good work to increase smoking cessation rates and improve air quality. International guidelines offer an overview of COPD care in all settings but there is still a need to develop management strategies which work locally and reflect the needs and perceptions of local physicians and patients. This new initiative has achieved both of these goals admirably.

Authors’ Affiliations

(1)
School of Ageing and Chronic Disease, University of Liverpool

References

  1. Celli BR, MacNee W: ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23 (6): 932-946.View ArticlePubMedGoogle Scholar
  2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013, 187 (4): 347-365. 10.1164/rccm.201204-0596PP.View ArticlePubMedGoogle Scholar
  3. Calverley PM, Albert P, Walker PP: Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med. 2013, 7: 564-573.View ArticleGoogle Scholar
  4. Calverley PM: The ABCD of GOLD made clear. Eur Respir J. 2013, 42 (5): 1163-1165.View ArticlePubMedGoogle Scholar
  5. O’Reilly J, Jones MM, Parnham J, Lovibond K, Rudolf M: Guideline Development Group: Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ. 2010, 340: c3134-10.1136/bmj.c3134.View ArticlePubMedGoogle Scholar

Copyright

© Calverley; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement